Genetic Technologies Limited (GENE) stock has risen 1.72% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With GENE Stock Today?
Genetic Technologies Limited (GENE) stock is lower by -0.42% while the S&P 500 is higher by 0.69% as of 10:48 AM on Monday, Oct 19. GENE is down -$0.01 from the previous closing price of $3.55 on volume of 217,914 shares. Over the past year the S&P 500 has risen 16.65% while GENE is higher by 63.13%. GENE lost -$0.62 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Genetic Technologies Limited click here.
More About Genetic Technologies Limited
Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.
Click Here to get the full Stock Score Report on Genetic Technologies Limited (GENE) Stock.